{"transactions":[{"id":1129171,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2025-05-30T18:52:21.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":107400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date."}],"balance_after":107400,"derivative":{"exercise_price":0.4444,"exercise_date":"2026-05-29","expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":107400},"source":{"system":"sec-edgar","filing":"0000950170-25-079947","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095017025079947/ownership.xml","form_type":"4"}},{"id":1217279,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrant (right to buy)","published_at":"2025-03-07T19:14:15.000Z","date":"2025-03-05","kind":"purchase","planned":false,"acquired":true,"shares":17857142,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an underwritten public offering, The Column Group Opportunity III, LP (\"TCG Opportunity III LP\") purchased units (the \"Units\") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\", and such shares, the \"Shares\"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a \"Series A Warrant\") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a \"Series B Warrant\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Series B Warrant is immediately exercisable (subject to certain beneficial ownership limitations)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":17857142,"derivative":{"exercise_price":0.7,"expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":17857142},"source":{"system":"sec-edgar","filing":"0000950170-25-035788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095017025035788/ownership.xml","form_type":"4"}},{"id":1217278,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant (right to buy)","published_at":"2025-03-07T19:14:15.000Z","date":"2025-03-05","kind":"purchase","planned":false,"acquired":true,"shares":35714284,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an underwritten public offering, The Column Group Opportunity III, LP (\"TCG Opportunity III LP\") purchased units (the \"Units\") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\", and such shares, the \"Shares\"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a \"Series A Warrant\") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a \"Series B Warrant\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Series A Warrant is immediately exercisable (subject to certain beneficial ownership limitations)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":35714284,"derivative":{"exercise_price":0.8,"expiration_date":"2030-03-04","underlying":"Common Stock","underlying_shares":35714284},"source":{"system":"sec-edgar","filing":"0000950170-25-035788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095017025035788/ownership.xml","form_type":"4"}},{"id":1217277,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-07T19:14:15.000Z","date":"2025-03-05","kind":"purchase","planned":false,"acquired":true,"shares":35714284,"price":0.7,"value":24999998.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an underwritten public offering, The Column Group Opportunity III, LP (\"TCG Opportunity III LP\") purchased units (the \"Units\") at a price per Unit of $0.70 per Unit. Each Unit consists of (a) one share of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\", and such shares, the \"Shares\"), (b) one Series A warrant to purchase one share of Common Stock at an exercise price of $0.80 per share which will expire five years from the date of issuance (a \"Series A Warrant\") and (c) one half of a Series B warrant to purchase a share of Common Stock at an exercise price of $0.70 per share that will expire on June 30, 2026 (a \"Series B Warrant\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the Issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":49313559,"source":{"system":"sec-edgar","filing":"0000950170-25-035788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095017025035788/ownership.xml","form_type":"4"}},{"id":1322891,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":84819,"kind":"organization","name":"COLUMN GROUP II, LP","position":1,"cik":"0001600420","reported_name":"COLUMN GROUP II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":84820,"kind":"organization","name":"Column Group II GP, LP","position":2,"cik":"0001645333","reported_name":"Column Group II GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84821,"kind":"organization","name":"PONOI CAPITAL, LP","position":3,"cik":"0001707230","reported_name":"PONOI CAPITAL, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84822,"kind":"organization","name":"Ponoi Management, LLC","position":4,"cik":"0001720702","reported_name":"Ponoi Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84823,"kind":"organization","name":"Ponoi Capital II, LP","position":5,"cik":"0001732601","reported_name":"Ponoi Capital II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84824,"kind":"organization","name":"Ponoi II Management, LLC","position":6,"cik":"0001746488","reported_name":"Ponoi II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":8,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":9,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84825,"kind":"organization","name":"Column Group LLC","position":10,"cik":"0001833486","reported_name":"Column Group LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to purchase)","published_at":"2024-12-23T17:57:58.000Z","date":"2024-12-23","kind":"other","planned":false,"acquired":true,"shares":1599417,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 23, 2024, The Column Group II, LP (\"TCG II LP\") and Ponoi Capital, LP (\"Ponoi LP\") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the \"Pre-Funded Warrants\"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 23, 2024, The Column Group II, LP (\"TCG II LP\") and Ponoi Capital, LP (\"Ponoi LP\") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the \"Pre-Funded Warrants\"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Ponoi LP. Ponoi Management, LLC (\"Ponoi LLC\") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the \"Ponoi Managing Partners\"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":1599417,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1599417},"source":{"system":"sec-edgar","filing":"0000950170-24-139754","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1732601/000095017024139754/ownership.xml","form_type":"4"}},{"id":1322890,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":84819,"kind":"organization","name":"COLUMN GROUP II, LP","position":1,"cik":"0001600420","reported_name":"COLUMN GROUP II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":84820,"kind":"organization","name":"Column Group II GP, LP","position":2,"cik":"0001645333","reported_name":"Column Group II GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84821,"kind":"organization","name":"PONOI CAPITAL, LP","position":3,"cik":"0001707230","reported_name":"PONOI CAPITAL, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84822,"kind":"organization","name":"Ponoi Management, LLC","position":4,"cik":"0001720702","reported_name":"Ponoi Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84823,"kind":"organization","name":"Ponoi Capital II, LP","position":5,"cik":"0001732601","reported_name":"Ponoi Capital II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84824,"kind":"organization","name":"Ponoi II Management, LLC","position":6,"cik":"0001746488","reported_name":"Ponoi II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":8,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":9,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84825,"kind":"organization","name":"Column Group LLC","position":10,"cik":"0001833486","reported_name":"Column Group LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to purchase)","published_at":"2024-12-23T17:57:58.000Z","date":"2024-12-23","kind":"other","planned":false,"acquired":true,"shares":1352008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 23, 2024, The Column Group II, LP (\"TCG II LP\") and Ponoi Capital, LP (\"Ponoi LP\") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the \"Pre-Funded Warrants\"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 23, 2024, The Column Group II, LP (\"TCG II LP\") and Ponoi Capital, LP (\"Ponoi LP\") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the \"Pre-Funded Warrants\"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by TCG II LP. The Column Group II GP, LP (\"TCG II GP\") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the \"TCG II GP Managing Partners\"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":1352008,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1352008},"source":{"system":"sec-edgar","filing":"0000950170-24-139754","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1732601/000095017024139754/ownership.xml","form_type":"4"}},{"id":1322889,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":84819,"kind":"organization","name":"COLUMN GROUP II, LP","position":1,"cik":"0001600420","reported_name":"COLUMN GROUP II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":84820,"kind":"organization","name":"Column Group II GP, LP","position":2,"cik":"0001645333","reported_name":"Column Group II GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84821,"kind":"organization","name":"PONOI CAPITAL, LP","position":3,"cik":"0001707230","reported_name":"PONOI CAPITAL, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84822,"kind":"organization","name":"Ponoi Management, LLC","position":4,"cik":"0001720702","reported_name":"Ponoi Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84823,"kind":"organization","name":"Ponoi Capital II, LP","position":5,"cik":"0001732601","reported_name":"Ponoi Capital II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84824,"kind":"organization","name":"Ponoi II Management, LLC","position":6,"cik":"0001746488","reported_name":"Ponoi II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":8,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":9,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84825,"kind":"organization","name":"Column Group LLC","position":10,"cik":"0001833486","reported_name":"Column Group LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T17:57:58.000Z","date":"2024-12-23","kind":"other","planned":false,"acquired":false,"shares":1599417,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 23, 2024, The Column Group II, LP (\"TCG II LP\") and Ponoi Capital, LP (\"Ponoi LP\") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the \"Pre-Funded Warrants\"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 23, 2024, The Column Group II, LP (\"TCG II LP\") and Ponoi Capital, LP (\"Ponoi LP\") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the \"Pre-Funded Warrants\"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Ponoi LP. Ponoi Management, LLC (\"Ponoi LLC\") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the \"Ponoi Managing Partners\"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-139754","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1732601/000095017024139754/ownership.xml","form_type":"4"}},{"id":1322888,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":84819,"kind":"organization","name":"COLUMN GROUP II, LP","position":1,"cik":"0001600420","reported_name":"COLUMN GROUP II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":84820,"kind":"organization","name":"Column Group II GP, LP","position":2,"cik":"0001645333","reported_name":"Column Group II GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84821,"kind":"organization","name":"PONOI CAPITAL, LP","position":3,"cik":"0001707230","reported_name":"PONOI CAPITAL, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84822,"kind":"organization","name":"Ponoi Management, LLC","position":4,"cik":"0001720702","reported_name":"Ponoi Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84823,"kind":"organization","name":"Ponoi Capital II, LP","position":5,"cik":"0001732601","reported_name":"Ponoi Capital II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84824,"kind":"organization","name":"Ponoi II Management, LLC","position":6,"cik":"0001746488","reported_name":"Ponoi II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":8,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":9,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84825,"kind":"organization","name":"Column Group LLC","position":10,"cik":"0001833486","reported_name":"Column Group LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T17:57:58.000Z","date":"2024-12-23","kind":"other","planned":false,"acquired":false,"shares":1352008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 23, 2024, The Column Group II, LP (\"TCG II LP\") and Ponoi Capital, LP (\"Ponoi LP\") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the \"Pre-Funded Warrants\"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 23, 2024, The Column Group II, LP (\"TCG II LP\") and Ponoi Capital, LP (\"Ponoi LP\") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the \"Pre-Funded Warrants\"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are directly held by TCG II LP. The Column Group II GP, LP (\"TCG II GP\") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the \"TCG II GP Managing Partners\"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0000950170-24-139754","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1732601/000095017024139754/ownership.xml","form_type":"4"}},{"id":1383480,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-10-21T20:37:30.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 31, 2025, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date."}],"balance_after":34000,"derivative":{"exercise_price":2.04,"exercise_date":"2025-05-31","expiration_date":"2034-10-17","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0000950170-24-116059","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095017024116059/ownership.xml","form_type":"4"}},{"id":1545506,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16806,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."}],"balance_after":0,"derivative":{"exercise_price":20.37,"expiration_date":"2030-05-19","underlying":"Common Stock","underlying_shares":16806},"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545505,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."}],"balance_after":0,"derivative":{"exercise_price":13.35,"expiration_date":"2029-05-14","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545504,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19619,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."}],"balance_after":0,"derivative":{"exercise_price":17.24,"expiration_date":"2031-06-07","underlying":"Common Stock","underlying_shares":19619},"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545503,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24222,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."}],"balance_after":0,"derivative":{"exercise_price":13.35,"expiration_date":"2032-05-07","underlying":"Common Stock","underlying_shares":24222},"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545502,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":78407,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F17","text":"Pursuant to the Merger Agreement, as of the Effective Time, each option was canceled for no consideration due to the exercise price of each such option exceeding the offer price of $1.55 per share."}],"balance_after":0,"derivative":{"exercise_price":3.69,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":78407},"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545501,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"other","planned":false,"acquired":true,"shares":1000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545500,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The securities were directly held by The Column Group Management LP (\"TCGM LP\"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545499,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545498,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1298908,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The securities were directly held by Ponoi Capital II, LP (\"Ponoi II LP\"). Ponoi II Management, LLC (\"Ponoi II LLC\") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545497,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1298908,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The securities were directly held by Ponoi Capital, LP (\"Ponoi LP\"). Ponoi Management, LLC (\"Ponoi LLC\") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545496,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2265758,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The securities were directly held by The Column Group II, LP (\"TCG II LP\"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545495,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":968990,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities were directly held by The Column Group III-A, LP (\"TCG III-A LP\"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities"}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545494,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":858035,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The securities were directly held by The Column Group III, LP (\"TCG III LP\"). The Column Group III GP, LP (\"TCG III GP\") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545493,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11103333,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The securities were directly held by TCG LP. TCG GP is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are the Reporting Person, a member of the Issuer's board of directors, and Peter Svennilson (collectively, the \"TCG Managing Partners\"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545492,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90442,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The securities were directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545491,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2650177,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The securities were directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545490,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":949862,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities were directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\"). (cont'd in FN5)"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(cont'd from FN 4) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545489,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":190000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities were directly held by the David V. Goeddel and Alena Z. Goeddel 2004 Trust and the Alena Z. Goeddel Irrevocable Trust for which the Reporting Person and Alena Z. Goeddel serve as co-trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1545488,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:02:22.000Z","date":"2024-04-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":134180,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. (\"Parent\") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent (\"Purchaser\") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the \"Effective Time\"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the \"TCG Rollover Agreement\"). (cont'd in FN2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(cont'd from FN1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the \"Stockholder Rollover Agreement\" and, together with the TCG Rollover Agreement, the \"Rollover Agreements\"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950142-24-000999","document":"eh240466973_4-goeddel.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095014224000999/eh240466973_4-goeddel.xml","form_type":"4"}},{"id":1643035,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T16:12:27.000Z","date":"2024-02-12","kind":"purchase","planned":false,"acquired":true,"shares":2222222,"price":4.5,"value":9999999.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from Footnote 1) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":13599275,"source":{"system":"sec-edgar","filing":"0000950170-24-015219","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095017024015219/ownership.xml","form_type":"4"}},{"id":1736580,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-17T16:25:42.000Z","date":"2023-11-16","kind":"purchase","planned":false,"acquired":true,"shares":5840,"price":0.6211,"value":3627.224,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6198 to $0.6221, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":949862,"source":{"system":"sec-edgar","filing":"0000950170-23-064842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095017023064842/ownership.xml","form_type":"4"}},{"id":1736579,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-17T16:25:42.000Z","date":"2023-11-16","kind":"purchase","planned":false,"acquired":true,"shares":1460,"price":0.6211,"value":906.806,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6198 to $0.6221, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."}],"balance_after":134180,"source":{"system":"sec-edgar","filing":"0000950170-23-064842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095017023064842/ownership.xml","form_type":"4"}},{"id":1736578,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-17T16:25:42.000Z","date":"2023-11-15","kind":"purchase","planned":false,"acquired":true,"shares":16791,"price":0.7075,"value":11879.6325,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.681 to $0.7201, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":944022,"source":{"system":"sec-edgar","filing":"0000950170-23-064842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095017023064842/ownership.xml","form_type":"4"}},{"id":1736577,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-17T16:25:42.000Z","date":"2023-11-15","kind":"purchase","planned":false,"acquired":true,"shares":2720,"price":0.7054,"value":1918.688,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.681 to $0.7201, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."}],"balance_after":132720,"source":{"system":"sec-edgar","filing":"0000950170-23-064842","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000095017023064842/ownership.xml","form_type":"4"}},{"id":1858663,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-06-12T20:14:37.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":29532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant  or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date."}],"balance_after":29532,"derivative":{"exercise_price":7.12,"exercise_date":"2024-06-09","expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":29532},"source":{"system":"sec-edgar","filing":"0001209191-23-036508","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000120919123036508/doc4.xml","form_type":"4"}},{"id":1894960,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-12T17:50:50.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":78407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date."}],"balance_after":78407,"derivative":{"exercise_price":3.69,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":78407},"source":{"system":"sec-edgar","filing":"0001209191-23-029185","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000120919123029185/doc4.xml","form_type":"4"}},{"id":1954068,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-14T16:09:49.000Z","date":"2023-03-10","kind":"purchase","acquired":true,"shares":6779,"price":2.5956,"value":17595.5724,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.58 to $2.60, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":11377053,"source":{"system":"sec-edgar","filing":"0000899243-23-008389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323008389/doc4.xml","form_type":"4"}},{"id":2022541,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-10T16:22:23.000Z","date":"2023-02-08","kind":"purchase","acquired":true,"shares":1500000,"price":2.6,"value":3900000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from Footnote 1) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":11370274,"source":{"system":"sec-edgar","filing":"0000899243-23-004580","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323004580/doc4.xml","form_type":"4"}},{"id":2038448,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-01T16:26:27.000Z","date":"2023-01-31","kind":"purchase","acquired":true,"shares":176730,"price":4.9986,"value":883402.578,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.995 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":927231,"source":{"system":"sec-edgar","filing":"0000899243-23-003129","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323003129/doc4.xml","form_type":"4"}},{"id":2038447,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-01T16:26:27.000Z","date":"2023-01-30","kind":"purchase","acquired":true,"shares":7542,"price":4.9996,"value":37706.9832,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.99 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":750501,"source":{"system":"sec-edgar","filing":"0000899243-23-003129","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323003129/doc4.xml","form_type":"4"}},{"id":2046356,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-25T16:26:03.000Z","date":"2023-01-23","kind":"purchase","acquired":true,"shares":9900,"price":4.9994,"value":49494.06,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.995 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":742959,"source":{"system":"sec-edgar","filing":"0000899243-23-002621","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323002621/doc4.xml","form_type":"4"}},{"id":2048619,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-23T16:21:10.000Z","date":"2023-01-19","kind":"purchase","acquired":true,"shares":69739,"price":2.4979,"value":174201.04810000001,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.35 to $2.57, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":9870274,"source":{"system":"sec-edgar","filing":"0000899243-23-002377","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323002377/doc4.xml","form_type":"4"}},{"id":2048618,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-23T16:16:35.000Z","date":"2023-01-20","kind":"purchase","acquired":true,"shares":500,"price":4.996,"value":2498.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":733059,"source":{"system":"sec-edgar","filing":"0000899243-23-002371","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323002371/doc4.xml","form_type":"4"}},{"id":2048617,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-23T16:16:35.000Z","date":"2023-01-19","kind":"purchase","acquired":true,"shares":37639,"price":4.9976,"value":188104.6664,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.975 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":732559,"source":{"system":"sec-edgar","filing":"0000899243-23-002371","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323002371/doc4.xml","form_type":"4"}},{"id":2050778,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-19T16:13:43.000Z","date":"2023-01-18","kind":"purchase","acquired":true,"shares":135688,"price":2.5163,"value":341431.7144,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.37 to $2.60, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":9800535,"source":{"system":"sec-edgar","filing":"0000899243-23-002158","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323002158/doc4.xml","form_type":"4"}},{"id":2050777,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-19T16:13:43.000Z","date":"2023-01-17","kind":"purchase","acquired":true,"shares":49463,"price":2.4947,"value":123395.3461,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.32 to $2.60, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":9664847,"source":{"system":"sec-edgar","filing":"0000899243-23-002158","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323002158/doc4.xml","form_type":"4"}},{"id":2053683,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-17T16:31:00.000Z","date":"2023-01-12","kind":"purchase","acquired":true,"shares":5378,"price":4.9466,"value":26602.8148,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.77 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":694920,"source":{"system":"sec-edgar","filing":"0000899243-23-001851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323001851/doc4.xml","form_type":"4"}},{"id":2055595,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-12T16:32:56.000Z","date":"2023-01-11","kind":"purchase","acquired":true,"shares":209000,"price":4.76,"value":994840.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":689542,"source":{"system":"sec-edgar","filing":"0000899243-23-001690","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323001690/doc4.xml","form_type":"4"}},{"id":2055594,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-12T16:32:56.000Z","date":"2023-01-10","kind":"purchase","acquired":true,"shares":100070,"price":4.8418,"value":484518.926,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.70 to $4.98, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":480542,"source":{"system":"sec-edgar","filing":"0000899243-23-001690","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924323001690/doc4.xml","form_type":"4"}},{"id":2086581,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-12-14T16:24:10.000Z","date":"2022-12-12","kind":"purchase","acquired":true,"shares":300,"price":4.9767,"value":1493.01,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.97 to $4.98, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":380472,"source":{"system":"sec-edgar","filing":"0000899243-22-038460","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322038460/doc4.xml","form_type":"4"}},{"id":2105148,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-23T16:11:06.000Z","date":"2022-11-22","kind":"purchase","acquired":true,"shares":4330,"price":4.9991,"value":21646.103,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Reporting Person, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":380172,"source":{"system":"sec-edgar","filing":"0000899243-22-036908","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322036908/doc4.xml","form_type":"4"}},{"id":2105147,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-23T16:11:06.000Z","date":"2022-11-21","kind":"purchase","acquired":true,"shares":35997,"price":4.9988,"value":179941.8036,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Reporting Person, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":375842,"source":{"system":"sec-edgar","filing":"0000899243-22-036908","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322036908/doc4.xml","form_type":"4"}},{"id":2105144,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-23T16:11:02.000Z","date":"2022-11-21","kind":"purchase","acquired":true,"shares":9615384,"price":2.6,"value":24999998.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"Managing Partners\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from Footnote 1) The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":9615384,"source":{"system":"sec-edgar","filing":"0000899243-22-036907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322036907/doc4.xml","form_type":"4"}},{"id":2123383,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-07T16:16:05.000Z","date":"2022-11-04","kind":"purchase","acquired":true,"shares":35058,"price":4.7156,"value":165319.5048,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.30 to $4.99, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Reporting Person, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting and investment power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":339845,"source":{"system":"sec-edgar","filing":"0000899243-22-035273","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322035273/doc4.xml","form_type":"4"}},{"id":2123382,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-07T16:16:05.000Z","date":"2022-11-03","kind":"purchase","acquired":true,"shares":104090,"price":4.9871,"value":519107.239,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.95 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Reporting Person, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting and investment power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":304787,"source":{"system":"sec-edgar","filing":"0000899243-22-035273","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322035273/doc4.xml","form_type":"4"}},{"id":2129515,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-31T17:20:59.000Z","date":"2022-10-27","kind":"purchase","acquired":true,"shares":76877,"price":4.8602,"value":373637.5954,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.795 to $4.90, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Reporting Person, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting and investment power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":200697,"source":{"system":"sec-edgar","filing":"0000899243-22-034564","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322034564/doc4.xml","form_type":"4"}},{"id":2130951,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T18:52:31.000Z","date":"2022-10-26","kind":"purchase","acquired":true,"shares":72774,"price":4.8512,"value":353041.2288,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.795 to $4.95, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 3 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Reporting Person, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting and investment power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":123820,"source":{"system":"sec-edgar","filing":"0000899243-22-034355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322034355/doc4.xml","form_type":"4"}},{"id":2130950,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-27T18:52:31.000Z","date":"2022-10-25","kind":"purchase","acquired":true,"shares":51046,"price":4.7484,"value":242386.8264,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.705 to $4.80, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group Opportunity III, LP (\"TCG Opportunity III LP\"). The Column Group Opportunity III GP, LP (\"TCG Opportunity III GP LP\") is the general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. TCG Opportunity III GP, LLC (\"TCG Opportunity III GP LLC\") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Reporting Person, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG Managing Members\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The TCG Managing Members may be deemed to share voting and investment power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":51046,"source":{"system":"sec-edgar","filing":"0000899243-22-034355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322034355/doc4.xml","form_type":"4"}},{"id":2134668,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-19T18:02:16.000Z","date":"2022-10-18","kind":"purchase","acquired":true,"shares":80000,"price":3.7907,"value":303256.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by the David V. Goeddel and Alena Z. Goeddel 2004 Trust for which the Reporting Person and Alena Z. Goeddel serve as co-trustee."}],"balance_after":190000,"source":{"system":"sec-edgar","filing":"0000899243-22-033838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322033838/doc4.xml","form_type":"4"}},{"id":2134667,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-10-19T18:02:16.000Z","date":"2022-10-17","kind":"purchase","acquired":true,"shares":50000,"price":3.1828,"value":159140.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $3.13 to $3.20, inclusive. The reporting person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."}],"balance_after":130000,"source":{"system":"sec-edgar","filing":"0000899243-22-033838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322033838/doc4.xml","form_type":"4"}},{"id":2234065,"issuer":{"id":6506,"kind":"organization","name":"Tenaya Therapeutics, Inc.","symbol":"TNYA"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2022-06-13T20:52:47.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":39727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant  or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date."}],"balance_after":39727,"derivative":{"exercise_price":5.26,"exercise_date":"2023-06-10","expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":39727},"source":{"system":"sec-edgar","filing":"0001209191-22-036525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000120919122036525/doc4.xml","form_type":"4"}},{"id":2234067,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-13T16:56:37.000Z","date":"2022-06-09","kind":"purchase","acquired":true,"shares":32477,"price":13.5,"value":438439.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":90442,"source":{"system":"sec-edgar","filing":"0000899243-22-022210","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322022210/doc4.xml","form_type":"4"}},{"id":2234066,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-13T16:56:37.000Z","date":"2022-06-09","kind":"purchase","acquired":true,"shares":951684,"price":13.5,"value":12847734.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":2650177,"source":{"system":"sec-edgar","filing":"0000899243-22-022210","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322022210/doc4.xml","form_type":"4"}},{"id":2242226,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T16:40:21.000Z","date":"2022-06-02","kind":"purchase","acquired":true,"shares":1129,"price":13.0333,"value":14714.5957,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.02 to $13.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":57965,"source":{"system":"sec-edgar","filing":"0000899243-22-021211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322021211/doc4.xml","form_type":"4"}},{"id":2242225,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T16:40:21.000Z","date":"2022-06-02","kind":"purchase","acquired":true,"shares":33071,"price":13.0333,"value":431024.2643,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.02 to $13.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1698493,"source":{"system":"sec-edgar","filing":"0000899243-22-021211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322021211/doc4.xml","form_type":"4"}},{"id":2247380,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-02T16:22:35.000Z","date":"2022-06-01","kind":"purchase","acquired":true,"shares":3036,"price":13.45,"value":40834.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.105 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":56836,"source":{"system":"sec-edgar","filing":"0000899243-22-020683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322020683/doc4.xml","form_type":"4"}},{"id":2247379,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-02T16:22:35.000Z","date":"2022-06-01","kind":"purchase","acquired":true,"shares":88964,"price":13.45,"value":1196565.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.105 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1665422,"source":{"system":"sec-edgar","filing":"0000899243-22-020683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322020683/doc4.xml","form_type":"4"}},{"id":2247378,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-02T16:22:35.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":2040,"price":13.4658,"value":27470.232,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.37 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":53800,"source":{"system":"sec-edgar","filing":"0000899243-22-020683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322020683/doc4.xml","form_type":"4"}},{"id":2247377,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-02T16:22:35.000Z","date":"2022-05-31","kind":"purchase","acquired":true,"shares":59766,"price":13.4658,"value":804797.0028,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.37 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1576458,"source":{"system":"sec-edgar","filing":"0000899243-22-020683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322020683/doc4.xml","form_type":"4"}},{"id":2251292,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-31T16:58:16.000Z","date":"2022-05-27","kind":"purchase","acquired":true,"shares":89,"price":13.4513,"value":1197.1657,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.35 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":51760,"source":{"system":"sec-edgar","filing":"0000899243-22-020199","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322020199/doc4.xml","form_type":"4"}},{"id":2251291,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-31T16:58:16.000Z","date":"2022-05-27","kind":"purchase","acquired":true,"shares":2621,"price":13.4513,"value":35255.8573,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.35 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1516692,"source":{"system":"sec-edgar","filing":"0000899243-22-020199","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322020199/doc4.xml","form_type":"4"}},{"id":2251290,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-31T16:58:16.000Z","date":"2022-05-26","kind":"purchase","acquired":true,"shares":667,"price":13.4935,"value":9000.1645,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.42 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":51671,"source":{"system":"sec-edgar","filing":"0000899243-22-020199","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322020199/doc4.xml","form_type":"4"}},{"id":2251289,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-31T16:58:16.000Z","date":"2022-05-26","kind":"purchase","acquired":true,"shares":19534,"price":13.4935,"value":263582.029,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.42 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1514071,"source":{"system":"sec-edgar","filing":"0000899243-22-020199","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322020199/doc4.xml","form_type":"4"}},{"id":2253753,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":84819,"kind":"organization","name":"COLUMN GROUP II, LP","position":1,"cik":"0001600420","reported_name":"COLUMN GROUP II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84820,"kind":"organization","name":"Column Group II GP, LP","position":2,"cik":"0001645333","reported_name":"Column Group II GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84821,"kind":"organization","name":"PONOI CAPITAL, LP","position":3,"cik":"0001707230","reported_name":"PONOI CAPITAL, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84822,"kind":"organization","name":"Ponoi Management, LLC","position":4,"cik":"0001720702","reported_name":"Ponoi Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84823,"kind":"organization","name":"Ponoi Capital II, LP","position":5,"cik":"0001732601","reported_name":"Ponoi Capital II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84824,"kind":"organization","name":"Ponoi II Management, LLC","position":6,"cik":"0001746488","reported_name":"Ponoi II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":8,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":9,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84825,"kind":"organization","name":"Column Group LLC","position":10,"cik":"0001833486","reported_name":"Column Group LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-27T16:24:59.000Z","date":"2022-05-25","kind":"purchase","acquired":true,"shares":63,"price":12.4549,"value":784.6587,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.44 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":42189,"source":{"system":"sec-edgar","filing":"0000899243-22-019937","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1732601/000089924322019937/doc4.xml","form_type":"4"}},{"id":2253752,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":84819,"kind":"organization","name":"COLUMN GROUP II, LP","position":1,"cik":"0001600420","reported_name":"COLUMN GROUP II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84820,"kind":"organization","name":"Column Group II GP, LP","position":2,"cik":"0001645333","reported_name":"Column Group II GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84821,"kind":"organization","name":"PONOI CAPITAL, LP","position":3,"cik":"0001707230","reported_name":"PONOI CAPITAL, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84822,"kind":"organization","name":"Ponoi Management, LLC","position":4,"cik":"0001720702","reported_name":"Ponoi Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84823,"kind":"organization","name":"Ponoi Capital II, LP","position":5,"cik":"0001732601","reported_name":"Ponoi Capital II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84824,"kind":"organization","name":"Ponoi II Management, LLC","position":6,"cik":"0001746488","reported_name":"Ponoi II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":8,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":9,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84825,"kind":"organization","name":"Column Group LLC","position":10,"cik":"0001833486","reported_name":"Column Group LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-27T16:24:59.000Z","date":"2022-05-25","kind":"purchase","acquired":true,"shares":1837,"price":12.4549,"value":22879.6513,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.44 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1236261,"source":{"system":"sec-edgar","filing":"0000899243-22-019937","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1732601/000089924322019937/doc4.xml","form_type":"4"}},{"id":2255133,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-26T16:07:55.000Z","date":"2022-05-25","kind":"purchase","acquired":true,"shares":1429,"price":13.4349,"value":19198.4721,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":51004,"source":{"system":"sec-edgar","filing":"0000899243-22-019685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322019685/doc4.xml","form_type":"4"}},{"id":2255132,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-26T16:07:55.000Z","date":"2022-05-25","kind":"purchase","acquired":true,"shares":41863,"price":13.4349,"value":562425.2187,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.25 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1494537,"source":{"system":"sec-edgar","filing":"0000899243-22-019685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322019685/doc4.xml","form_type":"4"}},{"id":2255131,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-26T16:07:55.000Z","date":"2022-05-24","kind":"purchase","acquired":true,"shares":588,"price":13.368,"value":7860.384,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.19 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":49575,"source":{"system":"sec-edgar","filing":"0000899243-22-019685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322019685/doc4.xml","form_type":"4"}},{"id":2255130,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-26T16:07:55.000Z","date":"2022-05-24","kind":"purchase","acquired":true,"shares":17240,"price":13.368,"value":230464.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.19 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1452674,"source":{"system":"sec-edgar","filing":"0000899243-22-019685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322019685/doc4.xml","form_type":"4"}},{"id":2256842,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":84819,"kind":"organization","name":"COLUMN GROUP II, LP","position":1,"cik":"0001600420","reported_name":"COLUMN GROUP II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84820,"kind":"organization","name":"Column Group II GP, LP","position":2,"cik":"0001645333","reported_name":"Column Group II GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84821,"kind":"organization","name":"PONOI CAPITAL, LP","position":3,"cik":"0001707230","reported_name":"PONOI CAPITAL, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84822,"kind":"organization","name":"Ponoi Management, LLC","position":4,"cik":"0001720702","reported_name":"Ponoi Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84823,"kind":"organization","name":"Ponoi Capital II, LP","position":5,"cik":"0001732601","reported_name":"Ponoi Capital II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84824,"kind":"organization","name":"Ponoi II Management, LLC","position":6,"cik":"0001746488","reported_name":"Ponoi II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":8,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":9,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84825,"kind":"organization","name":"Column Group LLC","position":10,"cik":"0001833486","reported_name":"Column Group LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T16:19:50.000Z","date":"2022-05-24","kind":"purchase","acquired":true,"shares":538,"price":12.0021,"value":6457.1298,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.605 to $12.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":42126,"source":{"system":"sec-edgar","filing":"0000899243-22-019470","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1732601/000089924322019470/doc4.xml","form_type":"4"}},{"id":2256841,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":84819,"kind":"organization","name":"COLUMN GROUP II, LP","position":1,"cik":"0001600420","reported_name":"COLUMN GROUP II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84820,"kind":"organization","name":"Column Group II GP, LP","position":2,"cik":"0001645333","reported_name":"Column Group II GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84821,"kind":"organization","name":"PONOI CAPITAL, LP","position":3,"cik":"0001707230","reported_name":"PONOI CAPITAL, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84822,"kind":"organization","name":"Ponoi Management, LLC","position":4,"cik":"0001720702","reported_name":"Ponoi Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84823,"kind":"organization","name":"Ponoi Capital II, LP","position":5,"cik":"0001732601","reported_name":"Ponoi Capital II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84824,"kind":"organization","name":"Ponoi II Management, LLC","position":6,"cik":"0001746488","reported_name":"Ponoi II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":8,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":9,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84825,"kind":"organization","name":"Column Group LLC","position":10,"cik":"0001833486","reported_name":"Column Group LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T16:19:50.000Z","date":"2022-05-24","kind":"purchase","acquired":true,"shares":15776,"price":12.0021,"value":189345.1296,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.605 to $12.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1234424,"source":{"system":"sec-edgar","filing":"0000899243-22-019470","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1732601/000089924322019470/doc4.xml","form_type":"4"}},{"id":2256840,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":84819,"kind":"organization","name":"COLUMN GROUP II, LP","position":1,"cik":"0001600420","reported_name":"COLUMN GROUP II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84820,"kind":"organization","name":"Column Group II GP, LP","position":2,"cik":"0001645333","reported_name":"Column Group II GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84821,"kind":"organization","name":"PONOI CAPITAL, LP","position":3,"cik":"0001707230","reported_name":"PONOI CAPITAL, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84822,"kind":"organization","name":"Ponoi Management, LLC","position":4,"cik":"0001720702","reported_name":"Ponoi Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84823,"kind":"organization","name":"Ponoi Capital II, LP","position":5,"cik":"0001732601","reported_name":"Ponoi Capital II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84824,"kind":"organization","name":"Ponoi II Management, LLC","position":6,"cik":"0001746488","reported_name":"Ponoi II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":8,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":9,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84825,"kind":"organization","name":"Column Group LLC","position":10,"cik":"0001833486","reported_name":"Column Group LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T16:19:50.000Z","date":"2022-05-23","kind":"purchase","acquired":true,"shares":338,"price":12.4993,"value":4224.7634,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.44 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":41588,"source":{"system":"sec-edgar","filing":"0000899243-22-019470","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1732601/000089924322019470/doc4.xml","form_type":"4"}},{"id":2256839,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":84819,"kind":"organization","name":"COLUMN GROUP II, LP","position":1,"cik":"0001600420","reported_name":"COLUMN GROUP II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84820,"kind":"organization","name":"Column Group II GP, LP","position":2,"cik":"0001645333","reported_name":"Column Group II GP, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84821,"kind":"organization","name":"PONOI CAPITAL, LP","position":3,"cik":"0001707230","reported_name":"PONOI CAPITAL, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84822,"kind":"organization","name":"Ponoi Management, LLC","position":4,"cik":"0001720702","reported_name":"Ponoi Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84823,"kind":"organization","name":"Ponoi Capital II, LP","position":5,"cik":"0001732601","reported_name":"Ponoi Capital II, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84824,"kind":"organization","name":"Ponoi II Management, LLC","position":6,"cik":"0001746488","reported_name":"Ponoi II Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":45898,"kind":"person","name":"Kutzkey Tim","position":7,"cik":"0001614186","reported_name":"Kutzkey Tim","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":8,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":64492,"kind":"person","name":"Svennilson Peter","position":9,"cik":"0001606074","reported_name":"Svennilson Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":84825,"kind":"organization","name":"Column Group LLC","position":10,"cik":"0001833486","reported_name":"Column Group LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-25T16:19:50.000Z","date":"2022-05-23","kind":"purchase","acquired":true,"shares":9898,"price":12.4993,"value":123718.0714,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.44 to $12.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1218648,"source":{"system":"sec-edgar","filing":"0000899243-22-019470","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1732601/000089924322019470/doc4.xml","form_type":"4"}},{"id":2259914,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-23T16:10:44.000Z","date":"2022-05-20","kind":"purchase","acquired":true,"shares":628,"price":13.4776,"value":8463.9328,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":48987,"source":{"system":"sec-edgar","filing":"0000899243-22-019205","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322019205/doc4.xml","form_type":"4"}},{"id":2259913,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-23T16:10:44.000Z","date":"2022-05-20","kind":"purchase","acquired":true,"shares":18406,"price":13.4776,"value":248068.7056,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1435434,"source":{"system":"sec-edgar","filing":"0000899243-22-019205","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322019205/doc4.xml","form_type":"4"}},{"id":2259912,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-23T16:10:44.000Z","date":"2022-05-19","kind":"purchase","acquired":true,"shares":682,"price":13.2547,"value":9039.7054,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.99 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":48359,"source":{"system":"sec-edgar","filing":"0000899243-22-019205","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322019205/doc4.xml","form_type":"4"}},{"id":2259911,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-23T16:10:44.000Z","date":"2022-05-19","kind":"purchase","acquired":true,"shares":19984,"price":13.2547,"value":264881.9248,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.99 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1417028,"source":{"system":"sec-edgar","filing":"0000899243-22-019205","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322019205/doc4.xml","form_type":"4"}},{"id":2261696,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-20T18:22:03.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":24222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date."}],"balance_after":24222,"derivative":{"exercise_price":13.35,"expiration_date":"2032-05-17","underlying":"Common Stock","underlying_shares":24222},"source":{"system":"sec-edgar","filing":"0001209191-22-031132","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000120919122031132/doc4.xml","form_type":"4"}},{"id":2263559,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-19T16:33:38.000Z","date":"2022-05-18","kind":"purchase","acquired":true,"shares":2067,"price":13.2039,"value":27292.4613,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.98 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":47677,"source":{"system":"sec-edgar","filing":"0000899243-22-018846","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018846/doc4.xml","form_type":"4"}},{"id":2263558,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-19T16:33:38.000Z","date":"2022-05-18","kind":"purchase","acquired":true,"shares":60583,"price":13.2039,"value":799931.8737,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.98 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1397044,"source":{"system":"sec-edgar","filing":"0000899243-22-018846","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018846/doc4.xml","form_type":"4"}},{"id":2263557,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-19T16:33:38.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":2939,"price":13.4171,"value":39432.8569,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.90 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":45610,"source":{"system":"sec-edgar","filing":"0000899243-22-018846","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018846/doc4.xml","form_type":"4"}},{"id":2263556,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-19T16:33:38.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":86110,"price":13.4171,"value":1155346.481,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.90 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1336461,"source":{"system":"sec-edgar","filing":"0000899243-22-018846","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018846/doc4.xml","form_type":"4"}},{"id":2267854,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T16:18:20.000Z","date":"2022-05-16","kind":"purchase","acquired":true,"shares":1094,"price":12.9015,"value":14114.241,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.05 to $13.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":42671,"source":{"system":"sec-edgar","filing":"0000899243-22-018397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018397/doc4.xml","form_type":"4"}},{"id":2267853,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T16:18:20.000Z","date":"2022-05-16","kind":"purchase","acquired":true,"shares":32072,"price":12.9015,"value":413776.908,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.05 to $13.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1250351,"source":{"system":"sec-edgar","filing":"0000899243-22-018397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018397/doc4.xml","form_type":"4"}},{"id":2267852,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T16:18:20.000Z","date":"2022-05-13","kind":"purchase","acquired":true,"shares":4269,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a purchase of common stock pursuant to a block trade at a price of $11.29 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":41577,"source":{"system":"sec-edgar","filing":"0000899243-22-018397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018397/doc4.xml","form_type":"4"}},{"id":2267851,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T16:18:20.000Z","date":"2022-05-13","kind":"purchase","acquired":true,"shares":125096,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a purchase of common stock pursuant to a block trade at a price of $11.29 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1218279,"source":{"system":"sec-edgar","filing":"0000899243-22-018397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018397/doc4.xml","form_type":"4"}},{"id":2271884,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T17:27:17.000Z","date":"2022-05-12","kind":"purchase","acquired":true,"shares":17,"price":11.8057,"value":200.6969,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.74 to $11.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":37308,"source":{"system":"sec-edgar","filing":"0000899243-22-018029","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018029/doc4.xml","form_type":"4"}},{"id":2271883,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T17:27:17.000Z","date":"2022-05-12","kind":"purchase","acquired":true,"shares":485,"price":11.8057,"value":5725.7645,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.74 to $11.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1093183,"source":{"system":"sec-edgar","filing":"0000899243-22-018029","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018029/doc4.xml","form_type":"4"}},{"id":2271882,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T17:27:17.000Z","date":"2022-05-12","kind":"purchase","acquired":true,"shares":2728,"price":11.6211,"value":31702.3608,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.73 to $11.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":37291,"source":{"system":"sec-edgar","filing":"0000899243-22-018029","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018029/doc4.xml","form_type":"4"}},{"id":2271881,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T17:27:17.000Z","date":"2022-05-12","kind":"purchase","acquired":true,"shares":79945,"price":11.6211,"value":929048.8395,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.73 to $11.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by The Column Group IV, LP (\"TCG IV LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC (\"TCG IV LLC\") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the \"TCG IV Managing Members\"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":1092698,"source":{"system":"sec-edgar","filing":"0000899243-22-018029","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018029/doc4.xml","form_type":"4"}},{"id":2271880,"issuer":{"id":11997,"kind":"organization","name":"NGM BIOPHARMACEUTICALS INC","symbol":"NGM"},"owners":[{"id":79074,"kind":"person","name":"GOEDDEL DAVID V","position":1,"cik":"0001182464","reported_name":"GOEDDEL DAVID V","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T17:27:17.000Z","date":"2022-05-11","kind":"purchase","acquired":true,"shares":88,"price":11.8473,"value":1042.5624,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.76 to $11.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by The Column Group IV-A, LP (\"TCG IV-A LP\"). The Column Group IV GP, LP (\"TCG IV GP LP\") is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities."}],"balance_after":34563,"source":{"system":"sec-edgar","filing":"0000899243-22-018029","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1182464/000089924322018029/doc4.xml","form_type":"4"}}],"next_cursor":"2022-05-13T17:27:17.000000Z,2271880"}